Sanofi (NASDAQ:SNY) Raised to Strong-Buy at Sanford C. Bernstein

Sanofi (NASDAQ:SNY) was upgraded by equities researchers at Sanford C. Bernstein to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

SNY has been the subject of a number of other reports. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Sanofi currently has an average rating of “Buy” and an average target price of $60.00.

Sanofi Price Performance

NASDAQ SNY opened at $54.34 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The stock’s 50-day moving average is $49.24 and its two-hundred day moving average is $52.27. The firm has a market cap of $137.91 billion, a P/E ratio of 27.72, a price-to-earnings-growth ratio of 1.21 and a beta of 0.57. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. On average, analysts anticipate that Sanofi will post 3.82 earnings per share for the current fiscal year.

Institutional Trading of Sanofi

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SNY. Hara Capital LLC grew its stake in shares of Sanofi by 16.2% in the 4th quarter. Hara Capital LLC now owns 4,888 shares of the company’s stock worth $236,000 after acquiring an additional 680 shares in the last quarter. Cardinal Capital Management raised its stake in shares of Sanofi by 1.9% during the 4th quarter. Cardinal Capital Management now owns 68,805 shares of the company’s stock valued at $3,318,000 after purchasing an additional 1,282 shares during the period. Kestra Investment Management LLC bought a new position in Sanofi in the 4th quarter worth about $84,000. Sierra Ocean LLC bought a new stake in shares of Sanofi during the fourth quarter valued at about $44,000. Finally, Keystone Financial Services boosted its position in shares of Sanofi by 2.0% in the fourth quarter. Keystone Financial Services now owns 13,883 shares of the company’s stock valued at $670,000 after acquiring an additional 278 shares during the period. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.